Drag a card by its title · ⚙ to size, swap or remove

The company

Metagenomi Therapeutics, Inc.

MGX · Nasdaq

Health CareBiotechnologyNot moving yet

MGX stood above a rising 150-day average in 3 of the last 52 weekly readings, and has been out of that trend for the last 49 weeks. It is 37.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 49
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $47K
Insider sales, 12 months: $53K
Officials’ trades on record: 0
Institutions holding: 43 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 3 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1

Sale orders, 12 months13

Buyers · sellers1 · 4

Who	Did	Shares	Traded
Laurence ReidDirector	bought	19,883at $1.17	9 Sep 2026filed 11 Sep 2026
Laurence ReidDirector	bought	117at $1.18	9 Sep 2026filed 11 Sep 2026
Pamela WapnickChief Financial Officer	sold	1,911at $1.16	8 Sep 2026filed 10 Sep 2026
Jian IrishDirector, Officer	sold	2,140at $1.16	8 Sep 2026filed 10 Sep 2026
Matthew WeinOfficer	sold	358at $1.16	8 Sep 2026filed 10 Sep 2026
Matthew WeinOfficer	sold	558at $1.30	5 Jun 2026filed 10 Jun 2026
Jian IrishDirector, Officer	sold	3,737at $1.30	5 Jun 2026filed 10 Jun 2026
Pamela WapnickChief Financial Officer	sold	2,884at $1.30	5 Jun 2026filed 10 Jun 2026
Jian IrishChief Executive Officer	sold	1,607at $1.60	5 Mar 2026filed 9 Mar 2026
Matthew WeinOfficer	sold	482at $1.60	5 Mar 2026filed 9 Mar 2026
Pamela WapnickChief Financial Officer	sold	1,581at $1.60	5 Mar 2026filed 9 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders43-2 on the quarter

New · exited5 · 7

Reported value$7.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026	1,077,700$1.3M	+19,756+1.9%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026	742,400$883K	-45,500−5.8%
Catalio Capital Management, LPunchanged · filed 14 Aug 2026	528,993$630K	00.0%
Peapod Lane Capital LLCadded · filed 27 Jul 2026	525,024$625K	+8,263+1.6%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026	513,701$611K	+16,934+3.4%
BRIDGEWAY CAPITAL MANAGEMENT, LLCadded · filed 14 Aug 2026	400,300$476K	+4,500+1.1%
WELLS FARGO & COMPANYadded · filed 14 Aug 2026	379,508$452K	+177,370+87.7%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026	288,665$344K	-69,535−19.4%
PURA VIDA INVESTMENTS, LLCunchanged · filed 13 Aug 2026	264,391$315K	00.0%
BlackRock, Inc.added · filed 7 Aug 2026	257,631$307K	+27,497+11.9%